Avadel to Unveil New Data on Lumryz for Narcolepsy Treatment
Avadel Pharmaceuticals will present new data supporting the clinical profile for Lumryz for narcolepsy in 12 abstracts at SLEEP 2023.
Source: sleepreviewmag.com
📰 Risk Evaluation News
Page 28 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
Despite growing use, abortion pill not 'safer than Tylenol' and carries serious risks, including trauma of flushing a baby down the toilet, pro-life experts say
(OSV News) -- More than 20 years ago, Toni McFadden took the abortion pill to end her pregnancy. She was a high school senior, the good girl in her family, and she did not want anyone to find out. She was about seven weeks pregnant when she took the regimens first drug -- mifepristone -- at an abortion clinic. She was sent home to take the second drug -- misoprostol -- at home. The doctor told her to expect bleeding like a heavy period. When she took the misoprostol, nothing happened. She ca
Source: thebostonpilot.com
The Mifepristone Case and the Legitimacy of the FDA
This Viewpoint discusses a recent federal court decision that invaliated the Food and Drug Administration’s (FDA) approval of mifepristone, a drug used to end p
Source: jamanetwork.com
Gilead Sciences, Inc.: Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
Source: finanznachrichten.de
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor... | June 1, 2023
Source: marketscreener.com
FDA Approves Extended-Release Injection for Opioid Use Disorder
TUESDAY, May 30, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Brixadi (buprenorphine) extended-release injection to treat moderate-to-severe opioid use disorder.
Robertm Califf Drug Administration Healthday News Risk Evaluation Mitigation Strategy Prevention Framework
Source: vtcng.com
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will...
United States Kelvin Tan Andrean Flynn Kristin Bhavnani Head Of Global Corporate Communications Jazz Pharmaceuticals
Source: prnewswire.com
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia DUBLIN, May 31, 2023 /PRNewswire/
United States Andrean Flynn Kelvin Tan Kristin Bhavnani International Classification Of Sleep Disorders Drug Administration
Source: finanznachrichten.de
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient... | June 10, 2023
Source: marketscreener.com
Regulatory Readiness Best Practices For Clinical Trial Compliance
Let’s face it: Clinical trials and, to some extent, their sponsoring companies can live and die by decisions made by the FDA. And while regulatory...
Source: clinicalleader.com